Maze Therapeutics Secures Up To $200M Term Loan Facility from Hercules Capital

summarizeSummary

Maze Therapeutics has secured a new senior secured term loan facility of up to $200 million from Hercules Capital, with an initial $40 million funded, replacing its previous loan agreement.

check_boxKey Events

• New Loan Facility Secured

  Maze Therapeutics entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200 million.

• Initial Funding Received

  An initial term loan of $40 million was funded on February 4, 2026, providing approximately $38.4 million in net proceeds after fees.

• Additional Capital Available

  Up to an additional $160 million in term loans is available over 60 months, contingent on satisfying certain conditions, financial covenants, and performance milestones.

• Loan Terms and Security

  The facility has a maturity date of February 1, 2031, accrues interest based on the prime rate, and is secured by a first lien on substantially all of the company's assets.

auto_awesomeAnalysis

Maze Therapeutics has secured a substantial new senior secured term loan facility, providing significant capital to support its operations and development. The initial funding of $40 million, with an additional $160 million available, represents a material liquidity injection for the company. This financing extends the company's financial runway and replaces its previous loan agreement with Banc of California, streamlining its debt structure. The facility is secured by a first lien on substantially all company assets and includes customary covenants and performance milestones for future tranches. Securing this financing while the stock trades near its 52-week high indicates a strong financial position and investor confidence.